Key takeaways
- 5-amino-1MQ is a small molecule; MOTS-c is a peptide.
- 5-amino-1MQ’s published studies are in cells and mice; they are not evidence of an effect in people.
- Human studies of MOTS-c measured the body’s own levels; we found no published study that gave it to people (PubMed and ClinicalTrials.gov, 21 November 2026).
- FDA staff recommended against adding MOTS-c to the 503A bulks list; HHS records that its advisory committee voted in favour, and its October 2026 draft policy, which “is not binding”, names MOTS-c. FDA’s 503A nominations list has no entry for 5-amino-1MQ.
- WADA’s 2026 and 2027 Lists name MOTS-c in S4.4.1, prohibited at all times; neither names 5-amino-1MQ, and for a substance it does not list WADA says “please verify its status with your Anti-Doping Organization”.
015-amino-1MQ vs MOTS-c in one table
Comparison based on the records cited below, checked on 21 November 2026. A blank in the evidence record is not a verdict about what future research may find.
| Question | 5-amino-1MQ | MOTS-c |
|---|---|---|
| Identity | 5-amino-1-methylquinolinium; a small molecule, not a peptide. PubChem lists formula C10H11N2+. | A 16-amino-acid peptide encoded in mitochondrial 12S rRNA; sequence MRWQEMGYIFYPRKLR. |
| Evidence described here | Cell studies (T4) and mouse studies (T3): 9 mice per cohort in a 2018 paper, 8 per group in a 2024 paper. Not evidence of an effect in people. | Cell (T4) and animal (T3) studies, not evidence of an effect in people; human studies measured the body’s own MOTS-c (T2). |
| Human data | We found no study that gave it to people (PubMed with its other names and human terms, and ClinicalTrials.gov, 21 Nov 2026). | We found no published study that gave it to people (PubMed and ClinicalTrials.gov, 21 Nov 2026); registered trial NCT07505745 has no posted results. Human studies measured the body’s own levels. |
| United States regulatory records | Drugs@FDA (through openFDA, data to 20 Nov 2026) lists no product with it as an active ingredient, and FDA’s 503A nominations list (updated 14 May 2026) has no entry for it (searched 21 Nov 2026). We draw no legal conclusion of our own. | FDA staff recommended against adding MOTS-c to the 503A bulks list (July 2026 briefing); HHS records that its advisory committee voted in favour of both forms. HHS’s October 2026 draft policy, which “is not binding”, names MOTS-c. |
| United Kingdom and Australia | UK: the emc medicines database returned no results for 5-amino-1MQ or methylquinolinium (21 Nov 2026); it is not the full UK register. Australia: the Poisons Standard October 2026 has no entry for 5-amino-1-methylquinolinium or methylquinolinium (searched 21 Nov 2026); we draw no scheduling conclusion of our own. | UK: the emc database returned no results for MOTS-c (21 Nov 2026); it is not the full UK register. Australia: The TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” MOTS-c has no entry by name in the Poisons Standard October 2026; we draw no scheduling conclusion of our own. |
| WADA sport status | Not named on the 2026 or 2027 List. For a substance it does not list, WADA says “please verify its status with your Anti-Doping Organization”; we draw no sport-status conclusion of our own. | Named in S4.4.1 (activators of AMPK) on the 2026 and 2027 Lists; S4 substances are prohibited at all times. |
02What differs between the molecules?
Small molecule
PubChem identifies 5-amino-1-methylquinolinium as a charged quinolinium compound. It is not a chain of amino acids.
Peptide
MOTS-c is a 16-amino-acid mitochondrial peptide. Its sequence and molecular identity do not make it the same kind of molecule as 5-amino-1MQ.
The comparison stops at identity and the evidence records. The cited material does not establish that the compounds have equivalent effects, risks, or uses. It also does not support a “which is better” answer.
When reading studies about either compound, start with what was actually tested: the molecule, model, and outcome. A result in a cell or animal model is not a result in people. A study of naturally occurring MOTS-c levels is also different from a study that administers MOTS-c. These distinctions matter before comparing evidence tiers or drawing conclusions about human effects.
For 5-amino-1MQ, the published work is in cells and mice. A 2018 paper examined it as an inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT) in cell assays and in mice fed a high-fat diet, 9 per cohort; a 2024 paper used the same kind of mouse model, 8 per group, and its authors declared competing interests. Both are T4 and T3 work, not evidence of an effect in people.
For MOTS-c, cell and animal research is separate from human observations of naturally occurring levels, which do not test what happens when MOTS-c is given. We found no published study that gave either compound to people (21 November 2026), so these records cannot compare the two in people.
If you are checking a MOTS-c report, the next practical question is what the report says about identity and purity. See how to read a COA, and the MOTS-c research guide for the compound-specific evidence record.
03What do the regulatory and sport records say?
Read the scope
An FDA compounding record addresses its stated compounding framework. It does not by itself answer every legal question about a compound or a person’s circumstances.
Read the List text
MOTS-c is named in the 2026 WADA List. For 5-amino-1MQ, absence by name is not a ruling on how the List applies; WADA directs readers to their anti-doping organization.
For MOTS-c in the United States, FDA’s July 2026 briefing says the nomination was withdrawn and that FDA evaluated MOTS-c at its own discretion; FDA staff recommended against adding it to the 503A bulks list, and HHS records that its advisory committee voted in favour of both forms. HHS’s October 2026 policy names MOTS-c; the Federal Register notice calls it a draft that “is not binding”.
For Australia, the October 2026 Poisons Standard does not name MOTS-c. We found no TGA statement applying any of its group entries to MOTS-c, and we draw no scheduling conclusion of our own. For the UK, the cited searches did not find a marketing authorisation or a UK law naming MOTS-c. These are limited document checks, not advice about individual conduct.
Sport status is a separate question from a country’s regulatory status. MOTS-c is explicitly named in the 2026 WADA List. For 5-amino-1MQ, the List text checked does not name the compound, but that search result is not a ruling that it is permitted. WADA itself advises readers to verify an unnamed substance with their anti-doping organization.
04What do the records establish—and what remains open?
Different molecule classes
One is a small molecule; the other is a peptide.
Same gap in people
Both have cell and animal studies; we found no published study that gave either to people.
Different records
Compounding and anti-doping records must be read in their own scope.
- Whether the cell and mouse findings for 5-amino-1MQ say anything about people: we found no study that tested it in people (21 November 2026).
- What registered MOTS-c trial NCT07505745 will report: no results were posted as of 21 November 2026.
- Whether the two compounds would differ in any human outcome. The cited evidence does not compare them in people.
- How a regulator or anti-doping organization would apply its rules to a specific person, product, or circumstance.
In short, the reliable comparison is about identity, the evidence currently described, and the scope of the records—not which compound is more effective. New human research or a change to a regulatory list could alter parts of this comparison, so check the dated primary records for decisions that matter to you.
This is a plain-English summary of the records cited here, checked on 21 November 2026. It is not legal or medical advice.